Mode
Text Size
Log in / Sign up
Phase 3 Completed N=679 Randomized Quadruple-blind Treatment

A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches

Migraine Disorders
Source: ClinicalTrials.gov NCT00156910 ↗
Enrolled (actual)
679
Serious AEs
5.2%
Results posted
Dec 2010
Primary outcomePrimary: Change in Frequency of Headache Episodes — 12.3; 13.4; -5.2; -5.3 Headache Episodes

Summary

This is a 60 week study including a double-blind phase followed by an open-label extension phase.

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Frequency of Headache Episodes
12.3; 13.4; -5.2; -5.3
SECONDARY
Change in Frequency of Headache Days
20.0; 19.8; -7.8; -6.4
SECONDARY
Change in Frequency of Acute Headache Pain Medication Intakes
29.1; 30.4; -10.3; -10.4
SECONDARY
Change in Frequency of Migraine/Probable Migraine Headache Days
19.1; 19.1; -7.6; -6.1
SECONDARY
Change in Frequency of Migraine/Probable Migraine Headache Episodes
11.5; 12.7; -4.8; -4.9

Eligibility Criteria

Inclusion Criteria

  • Frequent migraine (>=15 headache days per month)
  • >=4 distinct headache episodes lasting >=4 hours
  • >=50% of baseline headache days migraine/probable migraine days

Exclusion Criteria

  • Previous use of botulinum toxin of any serotype or immunization to any botulinum toxin serotype
  • Any medical condition that puts the patient at increased risk with exposure to BOTOX
  • Diagnosis of complicated migraine, chronic tension-type headache, hypnic headache, hemicrania continua, new daily persistent headache
  • Use of prophylactic headache medication within 28 days prior to week -4
  • Unremitting headache lasting continuously throughout the 4-week baseline period
  • Known or suspected Temporomandibular Disorders (TMD)
  • Diagnosis of fibromyalgia
  • Beck depression inventory score >24 at week-4
  • Psychiatric problems that may have interfered with study participation
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00156910). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search